![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, March 30, 2020 11:31:21 PM
Writing for RBC Capital, Randall Stanicky notes that while the guidance came in lower than he expected, he believes management is being conservative. Specifically, he points out that the company excluded contributions from Libervant, which will most likely go up for approval in late September, and said Parkinson's Disease treatment APL-130277 will only contribute a Q4 milestone payment.
Based on this development, Stanicky writes, "Our new estimates reflect these revisions though we see potential for numbers to move higher pending further visibility on Libervant launch timing and expectations."
"Overall, while our numbers have been revised modestly lower, our fundamental view of the story is unchanged; 2020 is set to be an inflection year with several updates that can drive the stock higher including anticipated approval of key value driver Libervant," continues Stanicky, who has an Outperform rating and $9 price target on AQST shares.
Stanicky's price target is the most conservative among analysts who have sounded off on this low-priced stock during the past three months. Three other Buy calls have included $10, $13 and even $36 targets, averaging out to a consensus PT of $17, or more than 380% upside over the next 52 weeks. Investors interested in learning more can see AQST analysis on TipRanks.
Recent AQST News
- Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024 • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 06/12/2024 09:14:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 04:36:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 04:35:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 12:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:52 PM
- Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 05:40:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 05:40:07 PM
- Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:23:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:21:49 PM
- Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/07/2024 08:19:11 PM
- Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film • GlobeNewswire Inc. • 04/29/2024 11:00:00 AM
- Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology • GlobeNewswire Inc. • 04/12/2024 08:01:00 PM
- Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock • GlobeNewswire Inc. • 03/25/2024 12:00:25 PM
- Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock • GlobeNewswire Inc. • 03/20/2024 01:49:43 AM
- Aquestive Therapeutics Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/19/2024 08:01:00 PM
- Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting • GlobeNewswire Inc. • 03/14/2024 09:23:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:36:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:36:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:35:52 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM